PDA Webinar: Utilization of Modular Manufacturing to Enhance/Upscale Capacity during COVID-19

Online
Ask a Question

The COVID-19 pandemic is pushing our industry to accelerate the development and supply of vaccines and treatments at a rate never seen before. The use of a pre-fabricated modular approach to designing and constructing cGMP manufacturing using autonomous cleanroom can be an effective approach at meeting these new challenges. The benefits and value of modular manufacturing can only be achieved through a partnership with regulators. The U.S. FDA has discussed the use of prefabricated modular manufacturing with industry stakeholders prior to the pandemic and will discuss how this technology may enable the rapid increases in capacity needed as a result of this global event.

The panel presentation will include technical, regulatory and industry leaders who will share their unique perspectives and experiences on how this critical technology can support advancing the manufacture of high-quality drugs that are not only safe and effective but can also be delivered to a global patient population expeditiously.

Takeaways:

  • An overview of the autonomous cleanroom system design and applications.
  • Comparison of traditional versus pre-fabricated offsite cleanroom construction.
  • Benefits of an autonomous cleanroom based facility approach. Specifically, as a response to the manufacturing needs as a result of the COVID-19 pandemic.
  • FDA stakeholder engagement activities related to prefabricated modular facilities.
  • General understanding of the regulatory challenges related to the implementation of mobile manufacturing.

Panelist include:

  • Merry Christie, PhD, Product Quality/CMC Team Lead, Office of Biological Products, Office of Pharmaceutical Quality, CDER, U.S. FDA (Invited)
  • Brian Horman, VP Facilities & Engineering, Just-Evotec Biologics
  • Laurie Norwood, President, Norwood Biologics Consulting LLC
  • Thomas O’Connor, PhD, Director, Division of Product Quality Research, Office of Testing and Research, Office of Pharmaceutical Quality, CDER, U.S. FDA
  • Dennis Powers, Vice President Business Development & Sales Engineering, G-CON Manufacturing Inc.

Submit Questions in advance for the Panel Discussion

More information coming soon.

GROUP REGISTRATION DISCOUNT: Register 3 people from the same organization as a group (at the same time) for the event and receive the 4th registration free. Other discounts cannot be applied.

GENERAL TERMS AND CONDITIONS: PDA will send you a confirmation letter within one week of payment being received. You must have this confirmation letter to be considered enrolled in a PDA event. If you have submitted a purchase order or requested an invoice, please be advised that a credit card guarantee is needed. PDA reserves the right to modify the material or speakers/trainers without notice or to cancel an event. If an event is cancelled, registrants will be notified by PDA immediately and will receive a credit (registration fee paid). PDA will not be responsible for any costs incurred by registrants due to cancellation. Please note that the attendee list is shared with attendees, trainers, and exhibitors and may be used to follow up on specific areas of interest after the event. Video, photo, and audio recordings are prohibited at all PDA events.

CANCELLATION: If a cancellation request is received 30 days before the event, a credit (registration fee paid minus a 200.00 USD/EUR processing fee) will be given. No credits will be given for cancellation requests received less than 30 days before the event. Cancellation requests must be emailed to [email protected].

PLEASE READ  PDA is not affiliated or contracted with any outside hotel contracting company. If someone other than PDA or the PDA chosen hotel contacts you suggesting that they represent any PDA event, they do not. It is PDA's recommendation that you book your hotel directly through the official PDA chosen hotel that is listed on our web site.